Subscribe to stay informed!
Malvern-based biopharmaceutical company Galera Therapeutics is filing for FDA approval of a new drug. The treatment, avasopasem, helps radiotherapy-induced severe oral mucositis, or…
Malvern-based Galera Therapeutics recently triggered a $37.5 million payment by completing enrollment for a late-stage study of Avasopasem. John George reported on…
Before we send you to this site, please subscribe to our daily newsletter.